Galectin-3: clinical utility and prognostic value in patients with heart failure

lectin-3: clinical utility and prognostic value in patients with heart failure Review (711) Total Article Views Authors: Kramer F Published Date February 2013 Volume 2013:4 Pages 13 - 22 DOI: http://dx.doi.org/10.2147/RRCC.S28562 Received: 06 December 2012 Accepted: 03 January 2013 Published: 07 February 2013 Frank Kramer Clinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, Germany Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.